Your browser doesn't support javascript.
loading
Association of State Insulin Out-of-Pocket Caps With Insulin Cost-Sharing and Use Among Commercially Insured Patients With Diabetes : A Pre-Post Study With a Control Group.
Garabedian, Laura F; Zhang, Fang; Costa, Rebecca; Argetsinger, Stephanie; Ross-Degnan, Dennis; Wharam, J Frank.
Affiliation
  • Garabedian LF; Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts (L.F.G., F.Z., R.C., S.A., D.R.).
  • Zhang F; Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts (L.F.G., F.Z., R.C., S.A., D.R.).
  • Costa R; Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts (L.F.G., F.Z., R.C., S.A., D.R.).
  • Argetsinger S; Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts (L.F.G., F.Z., R.C., S.A., D.R.).
  • Ross-Degnan D; Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts (L.F.G., F.Z., R.C., S.A., D.R.).
  • Wharam JF; Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, and Department of Medicine and Duke-Margolis Institute for Health Policy, Duke University, Durham, North Carolina (J.F.W.).
Ann Intern Med ; 177(4): 439-448, 2024 Apr.
Article in En | MEDLINE | ID: mdl-38527286
ABSTRACT

BACKGROUND:

Twenty-five states have implemented insulin out-of-pocket (OOP) cost caps, but their effectiveness is uncertain.

OBJECTIVE:

To examine the effect of state insulin OOP caps on insulin use and OOP costs among commercially insured persons with diabetes.

DESIGN:

Pre-post study with control group.

SETTING:

Eight states implementing insulin OOP caps of $25 to $30, $50, or $100 in January 2021, and 17 control states.

PARTICIPANTS:

Commercially insured persons with diabetes and insulin users younger than 65 years. Subgroups of particular interest included members from states with insulin OOP caps of $25 to $30, enrollees with health savings accounts (HSAs) that require high insulin OOP payments, and lower-income members. MEASUREMENTS Mean monthly 30-day insulin fills and OOP costs.

RESULTS:

State insulin caps were not associated with changes in insulin use in the overall population (relative change in fills per month, 1.8% [95% CI, -3.2% to 6.9%]). Insulin users in intervention states saw a 17.4% (CI, -23.9% to -10.9%) relative reduction in insulin OOP costs, largely driven by reductions among HSA enrollees; there was no difference in OOP costs among nonaccount plan members. More generous ($25 to $30) state insulin OOP caps were associated with insulin OOP cost reductions of 40.0% (CI, -62.5% to -17.6%), again primarily driven by a larger reduction in the subgroup with HSA plans.

LIMITATIONS:

Single national insurer; 9-month follow-up.

CONCLUSION:

Insulin OOP caps were associated with reduced insulin OOP costs but no overall increases in insulin use. A proposed national insulin cap of $35 for commercially insured persons might lead to meaningful insulin OOP savings but have a limited effect on insulin use. PRIMARY FUNDING SOURCE Centers for Disease Control and Prevention and National Institute of Diabetes and Digestive and Kidney Diseases.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus / Insulin Limits: Humans Country/Region as subject: America do norte Language: En Journal: Ann Intern Med Year: 2024 Type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus / Insulin Limits: Humans Country/Region as subject: America do norte Language: En Journal: Ann Intern Med Year: 2024 Type: Article